Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.39 |
| ▸ | PRKG1 | Q13976 | 8/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.33 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872869 | 0.86 | MAP2K2 (0.41) | ROCK2PRKG1MEN1KMT2ATDP1 | |
| SCHEMBL5872970 | 0.77 | MAP2K1 (0.42) | MEN1KMT2ATDP1IDO1 | |
| SCHEMBL5872899 | 0.77 | NPSR1 (0.39) | MEN1KMT2ATDP1IDO1 | |
| SCHEMBL5872911 | 0.76 | MEN1 (0.42) | MEN1KMT2ATDP1IDO1 | |
| SCHEMBL5872833 | 0.76 | MEN1 (0.39) | MEN1KMT2ATDP1IDO1 | |
| SCHEMBL5872786 | 0.72 | MEN1 (0.45) | MEN1KMT2ATDP1IDO1 | |
| SCHEMBL5872805 | 0.71 | ALDH1A1 (0.51) | CYP1A2MEN1KMT2A | |
| SCHEMBL5872904 | 0.71 | MAP2K1 (0.42) | MEN1KMT2ATDP1 | |
| SCHEMBL5872922 | 0.71 | MAPT (0.41) | MEN1KMT2ATDP1 | |
| SCHEMBL5872972 | 0.70 | MAPT (0.41) | MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001905-B2 | Substituted diarylamines as MEK inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | BIWERSI CATHLIN (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225076-A1 | 5-Amide substituted diarylamines as mex inhibitors | NRAS, MAPK6, MAPK12 | ROCK2 4315/4885PRKG1 1181/4885CYP1A2 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.